Evidence map›Paper›PMID 29062528›Full record

ArticleResearch involvement and engagement2017

Strengthening international patient advocacy perspectives on patient involvement in HTA within the HTAi Patient and Citizen Involvement Interest Group - Commentary.

Janet L Wale, Anna Mae Scott, Neil Bertelsen, Nick Meade, HTAi Patient and Citizen Involvement in HTA Interest Group (PCIG)

Abstract readEditorial
In one paragraph

Article in Research involvement and engagement, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Two decades of impact: lessons from the HTAi Patient and Citizen Involvement in HTA Interest Group.International journal of technology assessment in health care · 2026
    Article
  4. Article
  5. How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Citizens from 13 countries share similar preferences for COVID-19 vaccine allocation priorities.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janet L WalePatient advocate, 11A Lydia Street, Brunswick, Victoria 3056 Australia.
Anna Mae ScottCentre for Research in Evidence Based Practice, Bond University, Gold Coast, Queensland 4229 Australia.
Neil BertelsenNeil Bertelsen Consulting, Eisenacher Straße 3, 10777 Berlin, Germany.
Nick MeadeGenetic Alliance UK, Unit 4D Leroy House, 436 Essex Rd, London, N1 3QP UK.
HTAi Patient and Citizen Involvement in HTA Interest Group (PCIG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

plain language summaryHealth Technology Assessment (HTA) is an evidence-based decision-making process, focusing on evaluating health technologies for funding within a healthcare system. 'Health technologies' include medications, medical devices, diagnostics, medical procedures and services. Health Technology Assessment international (HTAi) is a global society for those who produce, use, participate in, or encounter HTA. The HTAi Secretariat supports special interest groups within HTAi. One such special interest group, the Patient and Citizen Involvement in HTA Interest Group (PCIG), focuses on strengthening patient involvement in HTA. PCIG's members are from HTA agencies, research, industry, and patient organisations. We describe the steps PCIG has taken to form an international panel of patient advocates (the Patient Panel) as an autonomous group within its governance structure that reports directly to the PCIG Steering Committee. The Patient Panel was established in order to strengthen meaningful patient involvement in HTA by working co-productively with other PCIG members to develop resources accessible to patient organisations. Patient advocates known to be active within HTA in their own countries were invited to form the inaugural group, with one person appointed to chair the group for the first year. Documentation had been prepared to inform potential members and set out potential roles as seen by the Steering Committee. The appointed Patient Panel is defining its own terms of reference, goals and objectives. The Panel Chair is a member of the PCIG Steering Committee, and is mentored by the retiring PCIG chair. A registry of activities is part of monitoring and evaluation. ABSTRACT:

Indexed as

Co-productionEvaluationHealth technology assessmentPatient and citizen involvement interest groupPatient engagementPatient involvement

Identifiers

PMID29062528
PMCPMC5611570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.